Reactivation of Cutaneous Leishmaniasis in a Rheumatoid Arthritis Patient Undergoing Tocilizumab Treatment
The American Journal of Tropical Medicine and Hygiene · 04.11.2026 · 115 (5) · 985-988
DOI: 10.4269/ajtmh.26-0345 ↗Kurz gefasst
Fallbericht in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, erschienen am 04.11.2026. Verfasst von Regina Maia de Souza und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Parasitologia, São Paulo, Universidade de São Paulo Instituto de Medicina Tropical de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Leishmaniasis, Cutaneous, Arthritis, Rheumatoid, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cutaneous leishmaniasis is a neglected vector-borne disease caused by Leishmania spp., with viable parasites potentially persisting after clinical cure. Immunosuppressive therapies may favor reactivation of latent infection. The case of a 62-year-old Brazilian woman with a 25-year history of rheumatoid arthritis who developed a painful ulcerative lesion on her right leg 1 month after initiating tocilizumab therapy is reported. Molecular testing confirmed Leishmania (Viannia) braziliensis , consistent with reactivated cutaneous leishmaniasis. Tocilizumab was discontinued, and liposomal amphotericin B was initiated but interrupted because of nephrotoxicity and hepatotoxicity. Despite incomplete treatment, the lesion gradually healed after withdrawal of immunosuppression without requiring additional antiparasitic therapy. Secondary prophylaxis with liposomal amphotericin B was subsequently initiated under close clinical and laboratory monitoring, and no recurrence has been observed during follow-up. This case highlights the importance of screening clinical history for prior leishmaniasis, maintaining vigilance for reactivation in patients from endemic areas, and promptly adjusting immunosuppressive therapy to optimize clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratório de Parasitologia, São Paulo, Universidade de São Paulo Instituto de Medicina Tropical de São Paulo, São Paulo, Brazil.
- Laboratório de Doenças Infecciosas e Emergentes, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.
- Faculdade de Medicina, Departamento de Infectologia e Medicina Tropical, São Paulo, Universidade de São Paulo, São Paulo, Brazil.
- Laboratório de Soroepidemiologia, São Paulo, Universidade de São Paulo Instituto de Medicina Tropical de São Paulo, São Paulo, Brazil.
Zitieren
APA
de Souza, R. M., Tuon, F. F., Nicodemo, A. C., Emori, C. T., Celeste, B. J., Arroyo Sanchez, M. C., & Amato, V. S. (2026). Reactivation of Cutaneous Leishmaniasis in a Rheumatoid Arthritis Patient Undergoing Tocilizumab Treatment. The American Journal of Tropical Medicine and Hygiene, 115(5), 985-988. https://doi.org/10.4269/ajtmh.26-0345
Vancouver
de Souza RM, Tuon FF, Nicodemo AC, Emori CT, Celeste BJ, Arroyo Sanchez MC, et al. Reactivation of Cutaneous Leishmaniasis in a Rheumatoid Arthritis Patient Undergoing Tocilizumab Treatment. The American Journal of Tropical Medicine and Hygiene. 2026;115(5):985-988. doi:10.4269/ajtmh.26-0345
BibTeX
@article{deSouza2026,
author = {de Souza, Regina Maia and Tuon, Felipe Francisco and Nicodemo, Antônio Carlos and Emori, Christini Takemi and Celeste, Beatriz Julieta and Arroyo Sanchez, Maria Carmen and Amato, Valdir Sabbaga},
title = {Reactivation of Cutaneous Leishmaniasis in a Rheumatoid Arthritis Patient Undergoing Tocilizumab Treatment},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2026},
volume = {115},
number = {5},
pages = {985--988},
doi = {10.4269/ajtmh.26-0345}
}
EUVIMED